Elucidation of mu-opioid gene structure: How genetics can help predict therapeutic response to opioids

European Journal of Pain Supplements

Volumn 5, Issue 2, 2011, Pages 433-438

  Diatchenko, Luda ^a   Elliott Robinson, J ^b   Maixner, William ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Opioid receptor (MOR); Analgesic response to opioids; Genetic association study; Opioid receptor gene (OPRM1) structure; Six transmembrane (6TM) MOR

Indexed keywords

BUPRENORPHINE; MORPHINE; MU OPIATE RECEPTOR; NALOXONE; NALTREXONE; OPIATE;

ALLELE; ARTICLE; COGNITIVE DEFECT; CONSTIPATION; DISEASE SEVERITY; DRUG MECHANISM; EXON; GENE LOCUS; GENE STRUCTURE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENETICS; HUMAN; HYPERALGESIA; HYPOTENSION; MIOSIS; MOLECULAR BIOLOGY; NAUSEA; NONHUMAN; PAIN; PRIORITY JOURNAL; PRURITUS; RESPIRATION DEPRESSION; SEDATION; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VOMITING;

EID: 83355160649     PISSN: 17543207     EISSN: 18780075     Source Type: Journal    
DOI: 10.1016/j.eujps.2011.08.022     Document Type: Article

References (55)

1. Befort K., Filliol D., Decaillot F.M., Gaveriaux-Ruff C., Hoehe M.R., Kieffer B.L. A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. J Biol Chem 2001, 276:3130-3137.
2. Beyer A., Koch T., Schroder H., Schulz S., Hollt V. Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J Neurochem 2004, 89:553-560.
3. Bond C., LaForge K.S., Tian M., Melia D., Zhang S., Borg L., et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA 1998, 95:9608-9613.
4. Bostrom E., Simonsson U.S., Hammarlund-Udenaes M. Oxycodone pharmacokinetics and pharmacodynamics in the rat in the presence of the P-glycoprotein inhibitor PSC833. J Pharm Sci 2005, 94:1060-1066.
5. Cadet P., Mantione K.J., Stefano G.B. Molecular identification and functional expression of mu 3, a novel alternatively spliced variant of the human mu opiate receptor gene. J Immunol 2003, 170:5118-5123.
6. Campa D., Gioia A., Tomei A., Poli P., Barale R. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther 2008, 83:559-566.
7. Camu F., Vanlersberghe C. Pharmacology of systemic analgesics. Best Pract Res Clin Anaesthesiol 2002, 16:475-488.
8. Chou W.Y., Wang C.H., Liu P.H., Liu C.C., Tseng C.C., Jawan B. Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology 2006, 105:334-337.
9. Chou W.Y., Yang L.C., Lu H.F., Ko J.Y., Wang C.H., Lin S.H., et al. Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol Scand 2006, 50:787-792.
10. Crain S.M., Shen K.F. Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability. Pain 2000, 84:121-131.
11. Dahan A., van Dorp E., Smith T., Yassen A. Morphine-6-glucuronide (M6G) for postoperative pain relief. Eur J Pain 2008, 12:403-411.
12. Diatchenko L., Nackley A.G., Tchivileva I.E., Shabalina S.A., Maixner W. Genetic architecture of human pain perception. Trends Genet 2007, 23:605-613.
13. Doyle G.A., Rebecca S.X., Lin S.S., Press D.M., Grice D.E., Buono R.J., et al. Identification of three mouse mu-opioid receptor (MOR) gene (Oprm1) splice variants containing a newly identified alternatively spliced exon. Gene 2007, 388:135-147.
14. Duguay Y., Baar C., Skorpen F., Guillemette C. A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity. Clin Pharmacol Ther 2004, 75:223-233.
15. Edwards R.R., Haythornthwaite J.A., Tella P., Max M.B., Raja S. Basal heat pain thresholds predict opioid analgesia in patients with postherpetic neuralgia. Anesthesiology 2006, 104:1243-1248.
16. Fortin J.P., Ci L., Schroeder J., Goldstein C., Montefusco M.C., Peter I., et al. The mu-opioid receptor variant N190K is unresponsive to peptide agonists yet can be rescued by small-molecule drugs. Mol Pharmacol 2010, 78:837-845.
17. Fukuda K., Hayashida M., Ikeda K., Koukita Y., Ichinohe T., Kaneko Y. Diversity of opioid requirements for postoperative pain control following oral surgery - is it affected by polymorphism of the mu-opioid receptor?. Anesth Prog 2010, 57:145-149.
18. Ginosar Y., Davidson E.M., Meroz Y., Blotnick S., Shacham M., Caraco Y. Mu-opioid receptor (A118G) single-nucleotide polymorphism affects alfentanil requirements for extracorporeal shock wave lithotripsy: a pharmacokinetic-pharmacodynamic study. Br J Anaesth 2009, 103:420-427.
19. Glass P.S.A. Intravenous drug delivery systems. Anesthesia 2000, 377-411. Livingston, Churchill. R.D. Miller (Ed.).
20. Goldstein F.J. Adjuncts to opioid therapy. J Am Osteopath Assoc 2002, 102:S15-S21.
21. Gris P., Gauthier J., Cheng P., Gibson D.G., Gris D., Laur O., et al. A novel alternatively spliced isoform of the mu-opioid receptor: functional antagonism. Mol Pain 2010, 6:33.
22. Hamabe W., Maeda T., Fukazawa Y., Kumamoto K., Shang L.Q., Yamamoto A., et al. P-glycoprotein ATPase activating effect of opioid analgesics and their P-glycoprotein-dependent antinociception in mice. Pharmacol Biochem Behav 2006, 85:629-636.
23. Han W., Ide S., Sora I., Yamamoto H., Ikeda K. A possible genetic mechanism underlying individual and interstrain differences in opioid actions: focus on the mu opioid receptor gene. Ann NY Acad Sci 2004, 1025:370-375.
24. Hayashida M., Nagashima M., Satoh Y., Katoh R., Tagami M., Ide S., et al. Analgesic requirements after major abdominal surgery are associated with OPRM1 gene polymorphism genotype and haplotype. Pharmacogenomics 2008, 9:1605-1616.
25. Inturrisi C.E. Clinical pharmacology of opioids for pain. Clin J Pain 2002, 18:S3-13.
26. Klepstad P., Rakvag T.T., Kaasa S., Holthe M., Dale O., Borchgrevink P.C., et al. The 118 A > G polymorphism in the human micro-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand 2004, 48:1232-1239.
27. Koch T., Kroslak T., Averbeck M., Mayer P., Schroder H., Raulf E., et al. Allelic variation S268P of the human mu-opioid receptor affects both desensitization and G protein coupling. Mol Pharmacol 2000, 58:328-334.
28. Kream RM, Sheehan M, Cadet P, Mantione KJ, Zhu W, Casares F, et al. Persistence of evolutionary memory: primordial six-transmembrane helical domain mu opiate receptors selectively linked to endogenous morphine signaling. Med Sci Monit 2007;13:SC5-SC6.
29. Kvam T.M., Baar C., Rakvag T.T., Kaasa S., Krokan H.E., Skorpen F. Genetic analysis of the murine mu opioid receptor: increased complexity of Oprm gene splicing. J Mol Med 2004, 82:250-255.
30. Lotsch J., Geisslinger G. Are mu-opioid receptor polymorphisms important for clinical opioid therapy?. Trends Mol Med 2005, 11:82-89.
31. Lotsch J., Skarke C., Grosch S., Darimont J., Schmidt H., Geisslinger G. The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics 2002, 12:3-9.
32. Matthes H.W., Maldonado R., Simonin F., Valverde O., Slowe S., Kitchen I., et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 1996, 383:819-823.
33. Mogil J.S. The genetic mediation of individual differences in sensitivity to pain and its inhibition. Proc Natl Acad Sci 1999, 96:7744-7751.
34. Mogil J.S., Wilson S.G., Bon K., Lee S.E., Chung K., Raber P., et al. Heritability of nociception I: responses of 11 inbred mouse strains on 12 measures of nociception. Pain 1999, 80:67-82.
35. North R.A. Membrane conductances and opioid receptor subtypes. NIDA Res Monogr 1986, 71:81-88.
36. Oertel B.G., Preibisch C., Wallenhorst T., Hummel T., Geisslinger G., Lanfermann H., et al. Differential opioid action on sensory and affective cerebral pain processing. Clin Pharmacol Ther 2008, 83:577-588.
37. Oertel B.G., Schmidt R., Schneider A., Geisslinger G., Lotsch J. The mu-opioid receptor gene polymorphism 118A>G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet Genom 2006, 16:625-636.
38. Pan Y.X. Diversity and complexity of the mu opioid receptor gene: alternative pre-mRNA splicing and promoters. DNA Cell Biol 2005, 24:736-750.
39. Pasternak G.W. Multiple opiate receptors: deja vu all over again. Neuropharmacology 2004, 47(Suppl. 1):312-323.
40. Ravindranathan A., Joslyn G., Robertson M., Schuckit M.A., Whistler J.L., White R.L. Functional characterization of human variants of the mu-opioid receptor gene. Proc Natl Acad Sci USA 2009, 106:10811-10816.
41. Ready L.B. Acute perioperative pain. Anesthesia 2000, 2323-2350. Livingston, Churchill. R.D. Miller (Ed.).
42. Reyes-Gibby C.C., Shete S., Rakvag T., Bhat S.V., Skorpen F., Bruera E., et al. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain 2007, 130:25-30.
43. Rowlingson J.C., Murphy T.M. Chronic pain. Anesthesia 2000, 7752-7755. Livingston, Churchill. R.D. Miller (Ed.).
44. Shabalina S.A., Zaykin D.V., Gris P., Ogurtsov A.Y., Gauthier J., Shibata K., et al. Expansion of the human mu-opioid receptor gene architecture: novel functional variants. Hum Mol Genet 2009, 18:1037-1051.
45. Sia A.T., Lim Y., Lim E.C., Goh R.W., Law H.Y., Landau R., et al. A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia. Anesthesiology 2008, 109:520-526.
46. Skarke C., Darimont J., Schmidt H., Geisslinger G., Lotsch J. Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. Clin Pharmacol Ther 2003, 73:107-121.
47. Somogyi A.A., Barratt D.T., Coller J.K. Pharmacogenetics of opioids. Clin Pharmacol Ther 2007, 81:429-444.
48. Sora I., Takahashi N., Funada M., Ujike H., Revay R.S., Donovan D.M., et al. Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc Natl Acad Sci USA 1997, 94:1544-1549.
49. Tan E.C., Lim E.C., Teo Y.Y., Lim Y., Law H.Y., Sia A.T. Ethnicity and OPRM variant independently predict pain perception and patient-controlled analgesia usage for post-operative pain. Mol Pain 2009, 5:32.
50. Thompson S.J., Koszdin K., Bernards C.M. Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology 2000, 92:1392-1399.
51. Tsai F.F., Fan S.Z., Yang Y.M., Chien K.L., Su Y.N., Chen L.K. Human opioid mu-receptor A118G polymorphism may protect against central pruritus by epidural morphine for post-cesarean analgesia. Acta Anaesthesiol Scand 2010, 54:1265-1269.
52. Uhl G.R., Sora I., Wang Z. The mu opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses. Proc Natl Acad Sci USA 1999, 96:7752-7755.
53. Xu J., Xu M., Hurd Y.L., Pasternak G.W., Pan Y.X. Isolation and characterization of new exon 11-associated N-terminal splice variants of the human mu opioid receptor gene. J Neurochem 2009, 108:962-972.
54. Zhang W., Chang Y.Z., Kan Q.C., Zhang L.R., Lu H., Chu Q.J., et al. Association of human micro-opioid receptor gene polymorphism A118G with fentanyl analgesia consumption in Chinese gynaecological patients. Anaesthesia 2010, 65:130-135.
55. Zhang W., Yuan J.J., Kan Q.C., Zhang L.R., Chang Y.Z., Wang Z.Y. Study of the OPRM1 A118G genetic polymorphism associated with postoperative nausea and vomiting induced by fentanyl intravenous analgesia. Minerva Anestesiol 2011, 77:33-39.